Filtered By:
Specialty: Drugs & Pharmacology
Condition: Thrombosis

This page shows you your search results in order of relevance. This is page number 15.

Order by Relevance | Date

Total 546 results found since Jan 2013.

Intravitreal Bevacizumab and Cardiovascular Risk in Patients with Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies
Conclusion Published data on IVTB in AMRD provide only a low level of evidence on its cardiovascular safety and do not support any finite conclusions.
Source: Drug Safety - March 7, 2016 Category: Drugs & Pharmacology Source Type: research

Establishing Edoxabans Role in Anticoagulation
Conclusion Based on the 3 clinical trials, edoxaban appears to be a safe and effective factor Xa inhibitor in patients with a creatinine clearance of <95 mL/min. It will serve as an alternative anticoagulant for those with a preference for once-daily dosing and/or taking medications that interact with the CYP450 system.
Source: Journal of Pharmacy Practice - May 10, 2016 Category: Drugs & Pharmacology Authors: Guirguis, E., Brown, D., Grace, Y., Patel, D., Henningfield, S. Tags: Review Articles Source Type: research

Is Dabigatran As Effective As Warfarin on Cardiac Thrombus in a Patient With Atrial Fibrillation? A Challenging Question
Atrial fibrillation (AF) is an important risk factor for cardioembolic stroke. Warfarin is an effective treatment in reducing the risk of cardioembolic stroke in patients with AF. New anticoagulants have been widely using for stroke prophylaxis in patients with nonvalvular AF. Previous studies have suggested that thrombolytic therapy is effective treatment choice in patients with pulmonary embolisms. Warfarin therapy is also effective on prevention or treatment of cardiac thrombus in patients with AF. However, there are no evidence-based data on treatment of cardiac thrombus with new oral anticoagulants in patients with AF...
Source: American Journal of Therapeutics - May 1, 2016 Category: Drugs & Pharmacology Tags: Case Reports Source Type: research

Edoxaban: A direct oral anticoagulant.
CONCLUSION: A review of the literature showed that edoxaban, the most recently approved DOAC, is noninferior to warfarin for management of VTE (after parenteral anticoagulant therapy) and for stroke risk reduction in many patients with nonvalvular AF. PMID: 28122753 [PubMed - in process]
Source: American Journal of Health-System Pharmacy : AJHP - January 28, 2017 Category: Drugs & Pharmacology Authors: Poulakos M, Walker JN, Baig U, David T Tags: Am J Health Syst Pharm Source Type: research

Non-Vitamin K antagonist Oral Anticoagulants: Impact of Non-adherence and Discontinuation.
Authors: Rivera-Caravaca JM, Esteve-Pastor MA, Roldán V, Marín F, Lip GYH Abstract INTRODUCTION: Non-Vitamin K Oral Anticoagulants (NOACs) are at least as effective as vitamin K antagonists (VKAs) reducing thromboembolism and mortality in atrial fibrillation (AF). These "fixed-dose regimen" drugs are characterized by not requiring routine monitoring or dosage adjustment. Stroke prevention with OAC is indicated in AF patients with CHA2DS2-VASc ≥2 (≥3 in females) and NOACs are recommended in preference to VKAs. However, underuse, premature discontinuation of treatment and non-adherence to guidelines is common, ...
Source: Expert Opinion on Drug Safety - July 6, 2017 Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research

Analysis of related factors of orolingual angioedema after rt-PA intravenous thrombolytic therapy.
CONCLUSIONS: Orolingual angioedema is a rare complication that occurs after rt-PA intravenous thrombolytic therapy; when serious, it may endanger a patient's life. If patients take an oral hypotension such as ACEI drugs before the onset of OA, they have a history of allergies, or the lesion is an infraction in the dominated area of the middle cerebral artery, the risk of OA after rt-PA intravenous thrombolytic therapy will be increased. The prevalence of OA should be monitored during the rt-PA intravenous thrombolytic therapy process; timely detection and early intervention should be conducted, which can avoid serious adve...
Source: European Review for Medical and Pharmacological Sciences - March 24, 2018 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Safety and Efficacy of Apixaban Versus Warfarin in Patients With Advanced Chronic Kidney Disease.
Conclusion and Relevance: Patients with advanced CKD taking apixaban had similar bleeding rates at 3 months compared with those taking warfarin. However, those who continued therapy had higher major bleeding rates with warfarin between 6 and 12 months. This study provides knowledge on the effects of a direct oral anticoagulant in a population that was excluded from all major trials. PMID: 29871510 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - June 1, 2018 Category: Drugs & Pharmacology Authors: Schafer JH, Casey AL, Dupre KA, Staubes BA Tags: Ann Pharmacother Source Type: research

Direct Oral Anticoagulants Versus Warfarin in the Treatment of Left Ventricular Thrombus.
CONCLUSION AND RELEVANCE: Our data suggest that DOACs may be reasonable alternatives for treatment of LV thrombus. When added to the totality of available studies, this study demonstrates that the effectiveness of DOACs in LV thrombus remains uncertain. Randomized clinical trials are needed. PMID: 33191781 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - November 15, 2020 Category: Drugs & Pharmacology Authors: Willeford A, Zhu W, Stevens C, Thomas IC Tags: Ann Pharmacother Source Type: research

Danhong injection combined with tPA protects the BBB through Notch-VEGF signaling pathway on long-term outcomes of thrombolytic therapy
In this study, the rats were randomly divided into sham group, vehicle group, DHI group (4 mL/kg), tPA group (5 mg/kg) and DHI+tPA group (4 mL/kg+ 2.5 mg/kg), administered intravenously 4.5 h since focal embolic stroke modeling. After 3 days and 7 days of cerebral ischemia, the neurological function of each treatment group was significantly improved compared with the vehicle group. The combination of DHI and tPA significantly reduced Evans blue (EB) penetration as well as the expressions of the proteins MMP-9, PAI-1 and P-selectin, while upregulating the expressions of claudin-5, occludin, and ZO-1 mRNA. Furthermore, the e...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - June 19, 2022 Category: Drugs & Pharmacology Authors: Simiao Chen Jinghui Zhang Min Li Jing Zhou Yuyan Zhang Source Type: research

Risk of thromboembolic events in non-hospitalized COVID-19 patients: A systematic review
Eur J Pharmacol. 2023 Jan 11:175501. doi: 10.1016/j.ejphar.2023.175501. Online ahead of print.ABSTRACTThe risk of thromboembolism in non-hospitalized COVID-19 patients remains uncertain and was assessed in this review to better weigh benefits vs. risks of prophylactic anticoagulation in this population. A search was performed through three databases: Medline, Embase, and Cochrane Library until 2022. Self-controlled case series, case-control and cohort studies were included, and findings summarized narratively. Meta-analyses for risk of thromboembolism including deep vein thrombosis (DVT), pulmonary embolism (PE), and myoca...
Source: European Journal of Pharmacology - January 14, 2023 Category: Drugs & Pharmacology Authors: Gaelle P Massoud Dana H Hazimeh Ghadir Amin Wissam Mekary Joanne Khabsa Tarek Araji Souha Fares Mathias Mericskay George W Booz Fouad A Zouein Source Type: research

Utilization of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention
ConclusionsThe utilization of TAT following PCI among high-stroke risk AF patients steadily increased from 2011 to 2020, reaching 65.4% by the end of the study period. However, in 2020, a significant proportion of 29.4% of patients still received DAPT, indicating that many AF patients undergoing PCI did not receive adequate antithrombotic therapy.
Source: European Journal of Clinical Pharmacology - February 24, 2023 Category: Drugs & Pharmacology Source Type: research

Neutrophil Extracellular Traps in Cerebral Ischemia/Reperfusion Injury: Friend and Foe
Curr Neuropharmacol. 2023 Mar 8. doi: 10.2174/1570159X21666230308090351. Online ahead of print.ABSTRACTCerebral ischemic injury, one of the leading causes of morbidity and mortality worldwide, triggers various central nervous system (CNS) diseases, including acute ischemic stroke (AIS) and chronic ischemia-induced Alzheimer's disease (AD). Currently, targeted therapies are urgently needed to address neurological disorders caused by cerebral ischemia/reperfusion injury (CI/RI), and the emergence of Neutrophil extracellular traps (NETs) may be able to relieve the pressure. Neutrophils are precursors to brain injury following...
Source: Current Neuropharmacology - March 9, 2023 Category: Drugs & Pharmacology Authors: Haoyue Luo Hanjing Guo Yue Zhou Rui Fang Wenli Zhang Zhigang Mei Source Type: research